GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Intrinsic Value: Projected FCF

Medexus Pharmaceuticals (TSX:MDP) Intrinsic Value: Projected FCF : C$3.31 (As of Jun. 19, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-19), Medexus Pharmaceuticals's Intrinsic Value: Projected FCF is C$3.31. The stock price of Medexus Pharmaceuticals is C$3.09. Therefore, Medexus Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.9.

The historical rank and industry rank for Medexus Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:

TSX:MDP' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.77   Med: 2.52   Max: 51.11
Current: 0.93

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Medexus Pharmaceuticals was 51.11. The lowest was 0.77. And the median was 2.52.

TSX:MDP's Price-to-Projected-FCF is ranked better than
75.4% of 618 companies
in the Drug Manufacturers industry
Industry Median: 1.6 vs TSX:MDP: 0.93

Medexus Pharmaceuticals Intrinsic Value: Projected FCF Historical Data

The historical data trend for Medexus Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Intrinsic Value: Projected FCF Chart

Medexus Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.41 -1.87 -2.44 -2.17 1.20

Medexus Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 1.20 2.37 2.70 3.31

Competitive Comparison of Medexus Pharmaceuticals's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Price-to-Projected-FCF falls into.


;
;

Medexus Pharmaceuticals Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Medexus Pharmaceuticals's Free Cash Flow(6 year avg) = C$4.30.

Medexus Pharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec24)*0.8)/Shares Outstanding (Diluted Average)
=(10.195616806174*4.30432+47.159*0.8)/24.675
=3.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals  (TSX:MDP) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Medexus Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3.09/3.3074933062271
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Executives
Brendon Buschman Senior Officer
Mike Mueller Director
Benoit Gravel Director
Stephen William Nelson Director
Kenneth D'entremont Director, Senior Officer
Marcel Pascal Konrad Senior Officer
Michael David Adelman Senior Officer
Glenn Tate Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Brian Peters Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin Senior Officer
Michael Pine Senior Officer
Richard Labelle Senior Officer
Benoît Hébert Senior Officer